Citron Provides New Proof Why Mallinckrodt is on its way to ZERO

,

Express Scripts lets the genie out the bottle!!!!

When Jim Chanos Speaks – Citron Listens.

First Enron, Then Valeant, Now Mallinckrodt.

 

Mallinckrodt is the most reviled company in the pharmaceutical industry.  Its unsavory business practices have only survived in the “post Valeant” era because of the direct business support of Express Scripts, their “co-conspirator”.

Two weeks ago at the SALT conference in Las Vegas, legendary short seller Jim Chanos described this unholy alliance, likening the Express Scripts companies’ role to Valeant’s Philidor.

Express Scripts has been taking so much heat from investors it was forced to throw Mallinckrodt under the bus.  But a typo prevented Wall Street from taking full notice of this sea change in Mallinckrodt’s fortunes.

For the rest of the story you won’t read anywhere else, Click Here: 

 

Could Blackberry be the Next NVIDIA?

,

Citron learns from history that we could be in the first stages of a “WOW” move from Blackberry

BlackBerry 24 month target:  $20. or  Likely Buyout Target at a Sizeable Premium

Blackberry as the next NVIDIA

An interesting point not known by most NVDA shareholders, and definitely not talked about on CNBC — While the enterprise value of NVDA stock has gone from $5 billion to $85 billion over the past 2 years…its revenues have only doubled.

Why? Because Wall Street stopped valuing NVDA as a graphic chip company and instead looked at its future in autonomous driving, AI, and datacenter tech. It wasn’t revenue growth that drove the stock, but rather what segment the growth was coming from.

So before you buy NVDA at $140, check out $BBRY.

Read the rest of the report here.

 

 

 

Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half

, , ,

Every Man and Woman Over The Age of 50 MUST read this report from Citron Research

Short term target:  $20.

3 to 5 Years:  Likely Single Digit, Potential 0.

Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.  That is why this $4 billion company is mainly owned by passive investing ETFs or other healthcare baskets.

More importantly, as Citron will expose, the key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its good or bad medicine.

For the rest of the story you won’t read anywhere else, click here: